REGENXBIO: Funding, Investors & Team (Oct 2026)
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
REGENXBIO has raised $290M across 2 funding rounds on record, the most recent an undisclosed round of $150M announced in May 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
REGENXBIO Company Profile and Key Stats
Latest funding round on record: May 2025.
REGENXBIO Funding Rounds
REGENXBIO raised $140M in an undisclosed round announced in Mar 2024.
1.2 years later, an undisclosed round of $150M was announced in May 2025.
REGENXBIO Founders and Leadership Team
Contact details for the REGENXBIO team: 1 of 2 have an email address on file.
Start 14-day free trial →REGENXBIO Funding Compared to Other Biotechnology Startups
REGENXBIO's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like REGENXBIO in Biotechnology and Rockville
Companies Similar to REGENXBIO
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
REGENXBIO Funding FAQs
What does REGENXBIO do?
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
How much funding has REGENXBIO raised?
REGENXBIO has raised $290M across 2 rounds on record. The most recent is an undisclosed round of $150M announced in May 2025.
When did REGENXBIO last raise funding?
REGENXBIO's most recent funding round on record is an undisclosed round of $150M, announced in May 2025.
Who founded REGENXBIO?
FundedIQ lists Kenneth Mills (Founder), Kenneth T Mills (Founder) at REGENXBIO.
Where is REGENXBIO headquartered?
REGENXBIO is based in Rockville, Maryland, United States.
How many employees does REGENXBIO have?
REGENXBIO is in the 251-500 employee band.
How does REGENXBIO's funding compare to other Biotechnology startups?
REGENXBIO's latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's REGENXBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for REGENXBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.